<DOC>
	<DOCNO>NCT02396433</DOCNO>
	<brief_summary>Non-randomized , open-label , multi-center , phase I/II , dose-escalation study combination carboplatin , eribulin , E7449 .</brief_summary>
	<brief_title>Combination Carboplatin , Eribulin Mesylate , E7449 BRCA-Related Cancers</brief_title>
	<detailed_description>This phase I/II clinical trial combination carboplatin , eribulin , E7449 . A cycle define 21 day . Carboplatin give day 1 cycle . Eribulin give day 1 8 cycle . E7449 give daily ( day 1-21 ) cycle . Patients continue receive treatment progression disease discontinuation due unacceptable side effect .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Phase I Patients must stage IV breast ovarian cancer another BRCA mutationrelated cancer . Patients may either measurable evaluable disease per RECIST 1.1 criterion . NOTE : Measurable lesion define accurately measure least one dimension ( long diameter record ) &gt; 20 mm conventional technique &gt; 10 mm spiral CT scan . Patients must refractory / intolerant establish therapy know provide clinical benefit condition . Both Phase I &amp; II Patients must archival biopsy specimen ( preferably metastatic disease ) available research test . If suitable biopsy specimen available , patient ask undergo research biopsy procure tissue . Patients must ≥ 18 year . Females childbearing potential must unprotected sexual intercourse within 30 day prior study entry must agree use highly effective method contraception . Females use hormonal contraceptive must stable dose hormonal contraceptive product least 4 week prior dose must continue use contraceptive study 30 day study drug discontinuation Patients must ECOG performance status 01 . Patients may prior diagnosis cancer &gt; 5 year since last treatment cancer . Patients must normal organ marrow function define : Leukocytes ≥ 3,000/μL Absolute neutrophil count ≥ 1,500/μL Platelets ≥ 100,000/μL Creatinine within normal limit creatinine clearance ≥30 Patients must able swallow retain oral medication . Patients receive prior systemic therapy : Prior treatment related side effect must resolve &lt; Grade 2 severity ( except alopecia infertility ) . All patient must give sign , informed consent prior registration study . Phase II Only Patients must stage IV breast ovarian cancer Patients must BRCA1/2 deleterious mutation , PTEN deficiency , cancer high HRD score assess Myriad 's assay Patients must measurable disease per RECIST 1.1 criterion ( see definition ) . Patients may receive 3 chemotherapeutic regimen metastatic disease . Patients may receive treatment prior carboplatin , eribulin PARP inhibitor . Women pregnant lactate eligible Patients undergo concomitant radiotherapy eligible . Patients receive investigational agent concurrent anticancer therapy eligible . NOTE : Previous systemic treatment allow 14 day ( Phase I ) 21 day ( Phase II ) washout period prior registration . Patients take herbal ( alternative ) medicine eligible . Patients must medications time registration . Patients know brain metastasis eligible participation unless follow met : Brain metastasis treat ( either surgical excision , stereotactic radiosurgery radiotherapy stable least 4 week ( MRI document ) Patient asymptomatic discontinue corticosteroid take purpose Patients follow condition complication NOT eligible participation : GI tract disease result inability take oral medication Malabsorption syndrome Require IV alimentation History prior surgical procedure affect absorption Uncontrolled inflammatory GI disease ( e.g. , Crohn 's , ulcerative colitis ) . Hypersensitivity component E7449 , carboplatin , eribulin History significant neurological ( neuropathy &gt; Grade 2 ) psychiatric disorder . Significant nonneoplastic liver disease ( e.g. , cirrhosis , active chronic hepatitis ) . Significant nonneoplastic renal disease . Immunocompromised subject , include subject know infected human immunodeficiency virus ( HIV ) . Uncontrolled endocrine disease ( e.g. , diabetes mellitus , hypothyroidism hyperthyroidism , adrenal disorder ) i.e. , require relevant change medication within last month hospital admission within last three month Active infection require systemic therapy . Significant cardiovascular impairment : history congestive heart failure great New York Heart Association ( NYHA ) Class II , uncontrolled arterial hypertension , unstable angina , myocardial infarction stroke within 6 month first dose study drug ; cardiac arrhythmia require medical treatment . Prolongation QTc interval &gt; 480 msec electrolyte balance normal . Major surgery within 4 week prior first dose study drug</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Halaven</keyword>
	<keyword>BRCA</keyword>
	<keyword>E7449</keyword>
</DOC>